Revenue and Profitability - Revenue for the third quarter decreased by 13.84% year-over-year, with total revenue reaching 6,176,286,324.36 RMB, a year-to-date decrease of 10.36%[2] - Net profit attributable to shareholders of the listed company dropped by 137.69% year-over-year for the third quarter, with a year-to-date net profit of 50,424,910.92 RMB, down 82.21%[2] - Total operating revenue for the first three quarters of 2024 was RMB 6,176,286,324.36, a decrease of 10.36% compared to RMB 6,890,332,466.40 in the same period of 2023[18] - Net profit attributable to the parent company's shareholders for the first three quarters of 2024 was RMB 50,424,910.92, a significant decrease of 82.21% compared to RMB 283,453,202.57 in the same period of 2023[22] - Revenue for the first three quarters of 2024 was RMB 1,294,991,244.54, a decrease of 42.1% compared to RMB 2,235,857,829.07 in the same period of 2023[29] - Operating profit for the first three quarters of 2024 was RMB 8,261,138.58, a significant drop from RMB 176,006,091.97 in the same period of 2023[30] - Net profit for the first three quarters of 2024 was RMB 14,557,299.52, compared to RMB 180,107,764.21 in the same period of 2023[30] Earnings Per Share (EPS) - Basic earnings per share (EPS) for the third quarter were -0.07 RMB, a decrease of 136.84% year-over-year[3] - Basic earnings per share for the first three quarters of 2024 were RMB 0.08, down 83.67% from RMB 0.49 in the same period of 2023[23] - Basic earnings per share for the first three quarters of 2024 were RMB 0.02, down from RMB 0.31 in the same period of 2023[30] Operating Costs and Expenses - Operating costs for the first three quarters of 2024 were RMB 4,592,846,859.28, down 10.11% from RMB 5,109,831,024.35 in the same period of 2023[18] - The company's operating costs did not decrease proportionally with revenue, further affecting profitability[8] - R&D expenses for the first three quarters of 2024 were RMB 81,276,813.53, a decrease of 21.22% compared to RMB 103,178,932.82 in the same period of 2023[18] Cash Flow and Liquidity - Operating cash flow for the year-to-date increased by 12.99% to 208,487,607.14 RMB[2] - Cash received from sales of goods and services in the first three quarters of 2024 was RMB 7,406,130,055.09, a slight decrease of 2.14% from RMB 7,568,518,985.69 in the same period of 2023[24] - Cash paid for goods and services in the first three quarters of 2024 was RMB 5,741,070,855.72, a slight decrease of 0.79% from RMB 5,786,996,990.39 in the same period of 2023[24] - Operating cash flow increased to 208,487,607.14 in Q3 2024, up from 184,520,267.81 in the previous period[25] - Net cash flow from financing activities turned positive at 51,465,972.24, compared to a negative -155,375,513.39 in the previous period[25] - Cash flow from operating activities for the first three quarters of 2024 was negative RMB 392,081,178.64, compared to positive RMB 241,511,156.96 in the same period of 2023[31] - Cash flow from investing activities for the first three quarters of 2024 was positive RMB 179,301,515.47, an increase from RMB 80,568,694.77 in the same period of 2023[31] - Cash flow from financing activities for the first three quarters of 2024 was positive RMB 230,642,952.33, compared to negative RMB 339,602,272.39 in the same period of 2023[31] - Total cash and cash equivalents at the end of the third quarter of 2024 were RMB 78,637,754.89, up from RMB 43,935,410.87 at the end of the same period in 2023[31] Assets and Liabilities - Total assets as of the end of the reporting period were 14,361,164,907.93 RMB, a slight increase of 0.36% compared to the end of the previous year[3] - Total assets grew to 8,496,828,306.32 as of September 30, 2024, up from 8,068,649,586.26 at the end of 2023[26] - Accounts receivable decreased to 1,139,809,345.70, down from 1,320,810,853.41 at the end of 2023[26] - Prepayments increased significantly to 1,414,438,728.31, more than double the 582,237,837.82 at the end of 2023[26] - Inventory decreased to 190,664,144.26, down from 383,639,633.70 at the end of 2023[26] - Total liabilities increased to 5,695,303,704.12, up from 5,241,745,365.60 at the end of 2023[27] - Short-term borrowings rose to 1,573,886,915.14, up from 1,324,854,032.14 at the end of 2023[27] - Equity decreased slightly to 2,801,524,602.20, down from 2,826,904,220.66 at the end of 2023[28] - Retained earnings decreased to 681,298,404.98, down from 726,627,397.66 at the end of 2023[28] Non-Recurring Items and Government Subsidies - Non-recurring gains and losses for the period amounted to 5,766,516.18 RMB, with government subsidies contributing 6,750,451.40 RMB[4][5] Credit Impairment and Investment Income - The company's gross margin remained relatively stable, but credit impairment losses increased significantly compared to the same period last year, impacting net profit[6] - Historical payment cycles from some hospital customers have lengthened, contributing to higher credit impairment losses[6] - Credit impairment losses for the first three quarters of 2024 were RMB -112,898,735.77, an increase of 66.94% compared to RMB -67,614,867.79 in the same period of 2023[18] - Investment income for the first three quarters of 2024 was RMB 97,818,515.41, a decrease of 48.59% compared to RMB 190,288,942.37 in the same period of 2023[18] Business Expansion and Costs - The company has been investing in new business expansion, leading to increased marginal costs[6] Comprehensive Income - Total comprehensive income for the first three quarters of 2024 was RMB 144,214,102.93, down 64.92% from RMB 411,095,919.44 in the same period of 2023[23]

| 证券代码：603108 | 证券简称：润达医疗 | 公告编号：临 | 2024-051 | | --- | --- | --- | --- | | 转债代码：113588 | 转债简称：润达转债 | | | 上海润达医疗科技股份有限公司 董事会决议公告 二、董事会会议审议情况 本次会议审议并通过如下议案： （一）审议通过了《关于审议公司2024年第三季度报告的议案》。 2024 年第三季度报告详见同日刊登在上海证券交易所网站（www.sse.com. cn）及《中国证券报》、《上海证券报》、《证券日报》、《证券时报》。 本议案已提交董事会审计委员会全票审议通过。 表决结果：同意 11 票，反对 0 票，弃权 0 票。 （二）审议通过了《关于全资子公司为公司发行公司债券提供反担保的议 案》。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 上海润达医疗科技股份有限公司（以下简称"公司"）第五届董事会第十七次 会议通知于2024年10月24日以邮件形式发出，会议于2024年10月28日（星期一） 15: ...

| 证券代码：603108 | 证券简称：润达医疗 | 公告编号：临 | 2024-054 | | --- | --- | --- | --- | | 转债代码：113588 | 转债简称：润达转债 | | | 上海润达医疗科技股份有限公司 关于召开 2024 年第二次临时股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 召开的日期时间：2024 年 11 月 14 日 13 点 30 分 召开地点：上海市虹口区乍浦路 89 号星荟中心 1 座 8 楼 (五) 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自 2024 年 11 月 14 日 至 2024 年 11 月 14 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 9:15-9:25，9:30-11:30，13:00-15:00；通过互 联网投票平台的投票时间为股东大会召开当日的 9:15-15:00。 (六) 融资融券、转 ...

| 证券代码：603108 | 证券简称：润达医疗 | 公告编号：临 | 2024-053 | | --- | --- | --- | --- | | 转债代码：113588 | 转债简称：润达转债 | | | 上海润达医疗科技股份有限公司 关于调整公司 2024 年度担保预计的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要提示： 本次调整公司 2024 年度担保预计情况如下： 新增对控股子公司润达供应链杭州提供担保 7,000 万元；新增对控股子 公司山东润达康源提供担保 500 万元；新增对控股子公司杭州铭和元提 供担保 1,000 万元；新增对控股子公司中鼎达科提供担保 1,500 万元； 公司为青岛益信预计提供担保由 20,000 万元减至 17,000 万元；为鑫海 润邦预计提供担保由 12,000 万元减至 10,000 万元；为其他合并报表范 围内下属子公司提供担保由 12,000 万元减至 7,000 万元；公司为子公司 预计提供担保的总额不变。 本次担保金额及已实际为其提供的担保余额：截至本公告披 ...

| 证券代码：603108 | 证券简称：润达医疗 | 公告编号：临 | 2024-052 | | --- | --- | --- | --- | | 转债代码：113588 | 转债简称：润达转债 | | | 上海润达医疗科技股份有限公司 关于全资子公司为公司发行公司债券提供反担保的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司 2024 年 10 月 28 日第五届董事会第十七次会议以全票同意的表决结果 审议通过了《关于全资子公司为公司发行公司债券提供反担保的议案》，本议案 尚需提交公司股东大会审议。 一、 反担保情况概述 为优化债务结构、降低融资成本，上海润达医疗科技股份有限公司（以下简 称"公司"）于 2024 年 6 月 27 日召开第五届董事会第十四次会议，会议审议通过 《关于注册公开发行公司债券的议案》，同意公司向中国证券监督管理委员会申 请注册总规模不超过人民币 10 亿元的公司债券。 为保证公司公开发行债券的顺利发行，拟由担保公司为债券发行提供担保， 同时公司全资子公司为该等担保提 ...

国金证券股份有限公司 关于上海润达医疗科技股份有限公司 不提前赎回"润达转债"的核查意见 国金证券股份有限公司（以下简称"本保荐机构"）作为上海润达医疗科技 股份有限公司（以下简称"润达医疗"、"公司"）公开发行可转换公司债券的 保荐机构，根据《证券发行上市保荐业务管理办法》、《上海证券交易所上市公 司自律监管指引第12号——可转换公司债券》等相关规定，对润达医疗不提前赎 回"润达转债"事项进行了认真、审慎的核查。核查的具体情况如下： 一、可转债发行上市基本情况 （一）经中国证券监督管理委员会证监许可[2020]586 号文核准，上海润达 医疗科技股份有限公司于 2020 年 6 月 17 日公开发行了 5,500,000 张（550,000 手）可转换公司债券，每张面值 100 元，发行总额 55,000 万元，发行期限 6 年， 票面利率分别为：第一年 0.3%、第二年 0.6%、第三年 1.0%、第四年 1.5%、第 五年 1.8%、第六年 2.0%。 度权益分派相应调整"润达转债"转股价格的公告》（公告编号：临 2023-065）。 因公司实施 2023 年度利润分配，自 2024 年 7 月 19 ...

| 证券代码：603108 | 证券简称：润达医疗 | 公告编号：临 | 2024-050 | | --- | --- | --- | --- | | 转债代码：113588 | 转债简称：润达转债 | | | 上海润达医疗科技股份有限公司 关于不提前赎回"润达转债"的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司股票自 2024 年 9 月 30 日至 2024 年 10 月 28 日期间，已满足连 续三十个交易日中至少有十五个交易日的收盘价不低于当期转股价格的 130%（含 130%）"，已触发"润达转债"的赎回条款。公司董事会决定本次 不行使"润达转债"的提前赎回权利，不提前赎回"润达转债"。 未来六个月内（即 2024 年 10 月 29 日至 2025 年 4 月 28 日），如公 司触发"润达转债"的赎回条款均不行使"润达转债"的提前赎回权利。以 2025 年 4 月 28 日之后的首个交易日重新起算，若"润达转债"再次触发赎 回条款，届时公司董事会将再次召开会议决定是否行使"润达转债" ...

| 证券代码：603108 | 证券简称：润达医疗 | 公告编号：临 | 2024-049 | | --- | --- | --- | --- | | 转债代码：113588 | 转债简称：润达转债 | | | 上海润达医疗科技股份有限公司 关于"润达转债"预计满足赎回条件的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、可转债发行上市概况 （一）经中国证券监督管理委员会证监许可[2020]586 号文核准，上海润达 医疗科技股份有限公司于 2020 年 6 月 17 日公开发行了 5,500,000 张（550,000 手）可转换公司债券，每张面值 100 元，发行总额 55,000 万元，发行期限 6 年， 票面利率分别为：第一年 0.3%、第二年 0.6%、第三年 1.0%、第四年 1.5%、第 五年 1.8%、第六年 2.0%。 t：指计息天数，即从上一个付息日起至本计息年度赎回日止的实际日历天 数（算头不算尾）。 若在前述三十个交易日内发生过转股价格调整的情形，则在调整前的交易日 按调整前的转股价格和 ...

Investment Rating - The investment rating for the company is "Buy" [7] Core Viewpoints - The company serves as an intermediary service provider for public medical institutions, offering a comprehensive testing service platform and expanding into IVD products and smart healthcare [2][3] - The company has established a strong presence across various regions in China, providing services to over 4,000 medical institutions, which positions it as a leader in the industry [3] - The collaboration with Huawei Cloud aims to develop AI models for the healthcare sector, enhancing service levels across different medical scenarios [4][5] - The "Xiao Hui" app is in the development and certification phase for the HarmonyOS, indicating the company's strategic positioning within the Huawei ecosystem [6] Summary by Sections Business Overview - The company generated revenue of 133 million yuan from its medical information business in 2023, accounting for 1.45% of total revenue, with a growth rate of 10.42% [2] - In the first half of 2024, the revenue from this segment reached 67 million yuan, representing 1.61% of total revenue, with a growth rate of 6.36% [2] Industry Position - The company has accumulated significant industry resources and data capabilities since 2010, allowing it to provide stable and efficient services nationwide [3] - The company has been recognized for its data governance capabilities, winning awards for its innovative projects in healthcare AI [3] Strategic Partnerships - The strategic partnership with Huawei Cloud includes the development of AI applications for healthcare, such as health assistants and digital services [4] - The company has launched several AI-driven products in collaboration with Huawei, enhancing its service offerings in health management and pharmacy [4] Financial Forecast - Revenue projections for 2024-2026 are 105.23 billion yuan, 121.85 billion yuan, and 141.01 billion yuan, with year-on-year growth rates of 15.04%, 15.79%, and 15.73% respectively [7] - The net profit attributable to the parent company is expected to be 3.89 billion yuan, 5.12 billion yuan, and 6.88 billion yuan for the same period, with growth rates of 42.25%, 31.81%, and 34.30% respectively [7]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 证券代码：603108 | 证券简称：润达医疗 | 公告编号：临 | 2024-046 | | --- | --- | --- | --- | | 转债代码：113588 | 转债简称：润达转债 | | | 上海润达医疗科技股份有限公司 一、担保情况概述 关于上月为子公司担保的进展情况公告 （一）为支持上海润达医疗科技股份有限公司（以下简称"公司"）全 资及控股子公司的发展，解决其流动资金短缺问题，经公司董事会及 2023 年度股东大会审议通过：自 2024 年 5 月 23 日至 2024 年度股东大会召开之 日期间，为公司全资及控股子公司向（类）金融机构申请总额不超过人民币 421,300 万元的授信额度提供连带责任保证担保，控股子公司其他股东提供 对等担保或为公司提供足额反担保，公司实际承担出资比例对应的担保金额。 被担保人名称：五家全资子公司：杭州润达、青岛益信、鑫海润邦、惠 中医疗、惠中生物；九家控股子公司：合肥润达、黑龙江龙卫、云南康 泰、武汉优科 ...